Compare Charles River Laboratories Intl. Inc (CRL) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Oxford Lane Capital Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B), while Oxford Lane Capital Corp trades at $9.52 (market cap $909.61M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 14.8× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 25.76% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | OXLC | |
|---|---|---|
Market Cap | $13.46B | $909.61M |
Sector | Health | Financials |
52-Week High | $282.00 | $18.75 |
52-Week Low | $145.57 | $8.15 |
Enterprise Value | $16.30B | — |
Dividend Yield | — | 25.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
OXLC trades at $9.52, up 2.7% today, with a bullish technical signal from moving averages but mixed oscillators. The stock shows a low P/B of 0.88 and a high P/S of 92.8, with recent earnings misses in Q1 and Q2 2026. Dividend payments of $0.20 per share continue monthly, supported by positive net cash flow of $252.37M in 2025. Revenue declined sharply to -$580M in 2026 from $57M in 2025, raising sustainability concerns.
Outlook is cautious due to volatile earnings and high yield risks; analyst consensus is split with 50% buy ratings. Key risks include negative ROE/ROA and potential NAV decay. Opportunities exist if dividend stability persists amid market discounts, but investor vigilance on financial health is critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
